Monash BDI researchers make Highly Cited list for the fourth consecutive year
Two Monash Biomedicine Discovery Institute (BDI) researchers have been recognised for their exceptional research performance, determined by production of multiple highly cited papers that rank in the top one per cent by citations for a field and year.
Professor Jamie Rossjohn and Professor Charles Mackay have each been ranked as a 2021 Highly Cited Researcher in the prestigious list released in November by Clarivate Analytics.
Professor Rossjohn’s research focus is on understanding, at the molecular level, how the T cell receptor specifically recognises polymorphic Human Leukocyte Antigen (HLA) molecules in the context of protective immunity, autoimmunity and other adverse T cell reactivities. Further, he has pioneered the molecular understanding of lipid and metabolite based immunity by T cells that recognise HLA class-I like molecules, CD1 and MR1, respectively. This is the fourth consecutive year that Professor Rossjohn has appeared on the Clarivate Analytics Highly Cited Researcher list.
Professor Mackay has forged a new understanding of the gut microbiome and the important role it plays in immune responses including allergies and in a number of diseases including type 1 diabetes. His research into how immune responses can be manipulated using 'medicinal foods', as well as novel gut microbial species, is attracting both clinical and public interest, with the latest research findings moving to clinical trials.
Professor Mackay was highly cited from 2005 to 2010 under what was then the Institute for Scientific Information citation, and has remained on the Clarivate Analytics Highly Cited Researcher list since 2017.
About the Monash Biomedicine Discovery Institute
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.